Race CEO Dr Daniel Tillett speaks to Nadine McGrath at Stockhead in detail about drug repurposing and resurrecting abandoned or underutilised drugs. Dr Tillet explains how commercial decisions contribute to whether a drug makes it to market or not. He…
Race Oncology (ASX:RAC) CEO Dr Daniel Tillett joins Sarah Hughan at the Stockhead’s What The Facts?! video interview series to discuss side effects of traditional chemotherapy and the importance of protecting heart health as patients go through cancer treatment. The damage to the…
We thank all our shareholders for their strong interest in the Race Oncology Bonus Options and Piggyback Options Offer. We have been receiving many questions in relation to these options, so to help we have prepared a document answering the…
Special Report: Race oncology is further bolstering the expertise of its scientific advisory board with the appointment of an international cardiometabolic expert who has researched the effects of chemotherapy on cardiovascular fitness of cancer patients. Clinical-stage biopharmaceutical company Race Oncology (ASX:RAC) has appointed…
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of…
For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions. Cardiovascular health problems are typically the most…
2024 Preview: Race Oncology (ASX:RAC) from Stockhead on Vimeo. Stockhead’s Ashtyn Hiron sits down with Race Oncology (ASX:RAC) CEO Daniel Tillett to close the books on 2023 and gain a sneak peek into what’s around the corner. The clinical stage biopharmaceutical company…
The Race Oncology Annual General Meeting was held on Monday 27 November 2023. During the meeting the Race Board and management team provided an update on the forward-looking strategy, detailed new clinical development plans and explained why we remain extremely…
Clincal stage biopharmaceutical company Race Oncology (ASX:RAC) says Tillett will work alongside executive director Dr Pete Smith, to advance the company’s strategic, clinical and commercialisation plans for its core asset reformulated bisantrene, RC220. Read more here.
Race Oncology has announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer. Dr Tillett’s appointment is effective immediately and he will work alongside Executive Director, Dr Pete Smith, to advance Race’s strategic, clinical and commercialisation plans for…
